The intra-tumoral administration of CCL21 or CCL19 ligands induces increased intratumoral influx of DCs and T cells, ultimately, reducing tumor growth and prolonging the survival of tumor-bearing mice [167,168,169,170,171]. This evidence concerns the gene CCL19 and neoplasm.